Loading...

Markus Muschen, MD, PhD

Title(s)Professor, Laboratory Medicine
SchoolSchool of Medicine
AddressLocation Required
Varies CA 00000
Phone415-502-0388
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Institute of Genetics, University of Cologne, Cologne, GermanyMD-PhD2003Department of Immunology
    University Medical Center Cologne, Cologne, GermanyClinical training2001Department of Haematology-Oncology
    University Medical Center Düsseldorf, GermanyPhysician-in-training2000Department of Medicine
    University of Dusseldorf, GermanyM.D.2000University Medical Center Düsseldorf
    University of Paris V, René Descartes, FranceMedical student1997Institut Pasteur
    University of Nantes, Nantes, FranceMedical student1995INSERM Unité 437, Transplantation Immunology
    Collapse Awards and Honors
    Howard Hughes Medical Institute2016HHMI Faculty Scholar Award
    National Cancer Institute2016NCI Outstanding Investigator Award
    Wellcome Trust2013Wellcome Trust Senior Investigator Award
    The Institute of Cancer Research, London, UK2012Haddow Professorship
    Leukemia and Lymphoma Society2010Scholar Award
    German Association of Hematology and Oncology2006Leukemia Research Award
    German Association for Immunology2004Fritz-Melchers Award
    University of Cologne2003Habilitation Thesis Award
    State of North-Rhine Westphalia2002Stem Cell Research Award
    German Science Foundation (DFG)2001Emmy-Noether Young Investigator Award
    Heinrich-Heine-Universitat Dusseldorf1999Doctoral Thesis Award

    Collapse Overview 
    Collapse Overview
    ACTIVE RESEARCH SUPPORT

    R01CA137060-A1 Müschen (PI) 04/01/2008 - 12/31/2012
    NCI/NIH
    “Pre-B cell receptor signaling in acute lymphoblastic leukemia”. The central goal of this project is to clarify the role of pre-B cell receptor signaling in acute lymphoblastic leukemia.

    R01CA139032 Müschen (PI) 04/01/2008 - 12/31/2012
    NCI/NIH
    “AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia”. The central goal is (1) to identify the regulatory mechanisms that lead to aberrant expression of AID and (2) to identify the consequences of aberrant AID-activity in leukemia cells.

    1R01CA157644 Müschen (PI) 04/01/2011-03/31/2016
    NIH/NCI
    ‘Infectious origins of childhood leukemia’. The central goal of this proposal is to experimentally test the ‘delayed infections hypothesis’ in the etiology of childhood ALL and to delineate mechanisms of genetic vulnerability of human pre-B cells in the context of infection.

    R21CA152497 Müschen (PI) 06/01/2010 - 05/31/2012
    NCI/NIH
    “Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia”. The central goals of this proposal are (1) to clarify the role of BCL6 in leukemia-initiation of Ph+ ALL and (2) To determine the frequency and phenotype of BCL6-dependent leukemia stem cells.

    TR2-01816 Müschen (PI) 10/01/2010-09/30/2013
    California Institute for Regenerative Medicine (CIRM)
    Early Translation Award. Development of a BCL6 small molecule inhibitor for targeted eradication of leukemia stem cells. The main goals of this project are (1) computer aided drug-design of BCL6 lateral groove inhibitors, (2) PK/PD assays and SAR studies of identified lead compound series and (3) pre-clinical validation.

    AACR 138564 Müschen (PI) 12/01/2009 - 11/30/2012
    AACR Stand Up To Cancer Innovation Award
    Stand Up To Cancer Innovation Award: Role of BCL6 in leukemia stem cell self-renewal. The main goal of this project is to study the role of BCL6 in the maintenance of leukemia-initiating cells in ALL.

    LLS 1497-11 Müschen (PI) 10/01/2010-09/30/2015
    The Leukemia and Lymphoma Society Scholar Award
    Leukemia and Lymphoma Society Scholar Award, will cover salary expenses related to NIH grant R01CA137060 ‘Pre-B cell receptor signaling in acute lymphoblastic leukemia’.

    LLS 6132-09 Müschen (PI) 10/01/2008-09/30/2012
    The Leukemia and Lymphoma Society
    Translational Research Grant ‘Targeting AID in BCR-ABL1-driven leukemia’. The main goal of this project is to study the role of AID in aberrant somatic hypermutation as a cause of genetic instability.

    LLS 6097-10 Müschen (PI) 07/01/2009-06/30/2013
    The Leukemia and Lymphoma Society
    Translational Research Grant ‘BCL6 in oncogene-induced senescence’. The main goal of this project is to study the role of BCL6 in oncogene-induced senescence in MYC-driven B cell lymphoma.

    LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
    Leukemia and Lymphoma Society SCOR
    Project 2: Dual targeting of tyrosine kinase and feedback signaling in leukemia. Goals are identification of novel oncogenic tyrosine kinases and characterization of feedback mechanisms in response to tyrosine kinase inhibition. Brian J Druker, Portland, OR is the PI of the SCOR.

    LLS 7005-11 Müschen (Project-PI) 10/01/2010-09/30/2015
    Leukemia and Lymphoma Society SCOR
    Core E: (1) Generate and make xenografted samples available to SCOR projects, (2) Generate a centralized multidimensional database which links flow cytometry data, cytogenetics, gene expression, SNP chip analysis and clinical information. Brian J Druker, Portland, OR is the PI of the SCOR.

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting oncogenic TCR signaling in PTCL
    NIH/NCI P01CA233412Sep 1, 2019 - Aug 31, 2024
    Role: Principal Investigator
    CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
    NIH/NCI R01CA213138Jun 1, 2017 - May 31, 2022
    Role: Principal Investigator
    Targeted activation of autoimmune checkpoints in B cell malignancies
    NIH/NCI R01CA157644Apr 4, 2017 - Mar 31, 2016
    Role: Principal Investigator
    Metabolic basis of B cell lineage leukemia relapse
    NIH/NCI R35CA197628Apr 1, 2017 - Mar 31, 2023
    Role: Principal Investigator
    Negative feedback signaling in tyrosine kinase-driven leukemia
    NIH/NCI R01CA172558Jul 1, 2013 - Apr 30, 2018
    Role: Principal Investigator
    Targeting BCL6 in tyrosine kinase-driven leukemia
    NIH/NCI R01CA169458May 15, 2013 - Apr 30, 2018
    Role: Principal Investigator
    Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia
    NIH/NCI R21CA152497Jul 1, 2010 - Jun 30, 2012
    Role: Principal Investigator
    AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
    NIH/NCI R01CA139032Mar 18, 2009 - Jan 31, 2015
    Role: Principal Investigator
    PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    NIH/NCI R01CA137060Dec 1, 2008 - Jan 31, 2019
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020 Sep 24; 136(13):1520-1534. Song C, Ge Z, Ding Y, Tan BH, Desai D, Gowda K, Amin S, Gowda R, Robertson GP, Yue F, Huang S, Spiegelman V, Payne JL, Reeves ME, Gurel Z, Iyer S, Dhanyamraju PK, Xiang M, Kawasawa YI, Cury NM, Yunes JA, McGrath M, Schramm J, Su R, Yang Y, Zhao Z, Lyu X, Muschen M, Payne KJ, Gowda C, Dovat S. PMID: 32396934.
      View in: PubMed   Mentions:    Fields:    
    2. Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun. 2017 10 17; 8(1):978. Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D. PMID: 29042531.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    3. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017 Jun 01; 127(6):2392-2406. Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. PMID: 28481221.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    4. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. PMID: 27479034.
      View in: PubMed   Mentions: 15     Fields:    
    5. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. PMID: 27070704.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    6. Inhibition of IRE1a-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 05; 7(14):18736-49. Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP. PMID: 26934650.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    7. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016 Apr; 22(4):379-87. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PMID: 26974310.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    8. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 04 28; 127(17):2131-43. Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. PMID: 26864341.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    9. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 06; 30(6):1246-54. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA. PMID: 26847027.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    10. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016 05; 30(5):1155-65. Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP. PMID: 26847029.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    11. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. PMID: 26711339.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    12. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia. 2016 06; 30(6):1436-40. Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. PMID: 26639180.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    13. Infection and the Perils of B-cell Activation. Cancer Discov. 2015 Dec; 5(12):1244-6. Greaves M, Müschen M. PMID: 26637659.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    14. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 05; 126(19):2202-12. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. PMID: 26324703.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    15. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. 2015 Oct 08; 126(15):1813-22. Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S. PMID: 26219304.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    16. Infectious origins of childhood leukemia. Oncotarget. 2015 Jul 10; 6(19):16798-9. Swaminathan S, Müschen M. PMID: 26196452.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    17. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):114-28. Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. PMID: 26073130.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    18. HSP90 inhibitors decrease AID levels and activity in mice and in human cells. Eur J Immunol. 2015 Aug; 45(8):2365-76. Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. PMID: 25912253.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    19. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015 Jul; 16(7):766-774. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M. PMID: 25985233.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    20. Ph+ ALL: drawing strength from a benign past. Blood. 2015 May 07; 125(19):2879-80. Müschen M. PMID: 25953975.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    21. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015 Apr 22; 8:39. Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. PMID: 25895498.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    22. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015 Jun 11; 125(24):3688-93. Müschen M. PMID: 25878119.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    23. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21; 521(7552):357-61. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. PMID: 25799995.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    24. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun. 2015 Mar 10; 6:6471. Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. PMID: 25753524.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    25. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. PMID: 25759025.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    26. Human lymphoid translocation fragile zones are hypomethylated and have accessible chromatin. Mol Cell Biol. 2015 Apr; 35(7):1209-22. Lu Z, Lieber MR, Tsai AG, Pardo CE, Müschen M, Kladde MP, Hsieh CL. PMID: 25624348.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    27. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunol Rev. 2015 Jan; 263(1):192-209. Buchner M, Swaminathan S, Chen Z, Müschen M. PMID: 25510278.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    28. Follicular lymphoma: too many reminders for a memory B cell. J Clin Invest. 2014 Dec; 124(12):5095-8. Swaminathan S, Müschen M. PMID: 25384212.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    29. Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. Sci Rep. 2014 Oct 09; 4:6565. Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK. PMID: 25298122.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    30. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014 Jul; 21(4):341-9. Buchner M, Müschen M. PMID: 24811161.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    31. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):E2219-28. Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. PMID: 24821775.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    32. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 2014 Jan 15; 5(1):211-23. Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, Müschen M, Chen CC. PMID: 24457556.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    33. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb; 46(2):116-25. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. PMID: 24413735.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    34. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. PMID: 24346116.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCells
    35. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol. 2014 Mar; 35(3):131-7. Swaminathan S, Duy C, Müschen M. PMID: 24332591.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    36. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia. 2014 Jan; 28(1):216-20. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Müschen M, Meeker N, Trede N, Frazer JK, Zhou Y, Cheng C, Jeha S, Pui CH, Willman CL, Harvey RC, Hunger SP, Yang JJ, Barnette P, Mullighan CG, Miles RR, Schiffman JD. PMID: 23881307.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013 Aug; 19(8):1014-22. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. PMID: 23852341.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    38. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013 Aug 15; 122(7):1293-304. Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. PMID: 23836560.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    39. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2014 Apr 24; 33(17):2169-78. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM. PMID: 23728349.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    40. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. J Exp Med. 2013 Apr 08; 210(4):805-19. Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. PMID: 23478187.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    41. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood. 2013 Mar 07; 121(10):1814-8. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM. PMID: 23319569.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    42. Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation. Mol Cell Biol. 2013 Mar; 33(5):947-57. Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR. PMID: 23263985.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    43. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 03; 121(1):148-55. Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. PMID: 23152540.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    44. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):656-67. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. PMID: 23153538.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    45. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012 Nov; 2(11):1004-23. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. PMID: 23107779.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    46. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One. 2012; 7(7):e40934. Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foà R, Baccarani M, Müschen M, Perini G, Martinelli G. PMID: 22848414.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    47. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood. 2012 Jun 14; 119(24):5621-31. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Müschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS. PMID: 22490804.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    48. Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity. 2011 Dec 23; 35(6):883-96. Jiang XX, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P, Jones L, Wang L, Won H, Lee HR, Jung JU, Müschen M, Huang XF, Chen SY. PMID: 22169041.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCells
    49. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. PMID: 21911423.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    50. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Oct 13; 118(15):4174-8. Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. PMID: 21856866.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    51. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011 Aug 25; 118(8):2191-9. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. PMID: 21715311.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimals
    52. American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation. Am J Blood Res. 2011; 1(1):106-9. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Müschen M, Wang D. PMID: 22432071.
      View in: PubMed   Mentions:
    53. Launching of american journal of blood research. Am J Blood Res. 2011; 1(1):i. Kwak LW, Goldenberg DM, Benz EJ, Yi Q, Muschen M, Wang D. PMID: 22432072.
      View in: PubMed   Mentions:
    54. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 May 19; 473(7347):384-8. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. PMID: 21593872.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansAnimalsCells
    55. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15; 17(10):3219-32. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. PMID: 21474579.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    56. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal. 2011 Mar 29; 4(166):ra18. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. PMID: 21447799.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    57. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011 Feb; 25(2):290-300. Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J. PMID: 21102429.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    58. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010 Oct 01; 70(19):7411-20. Gruber TA, Chang MS, Sposto R, Müschen M. PMID: 20876806.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    59. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 2010 Nov 01; 70(21):8299-308. Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG. PMID: 20837665.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    60. Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila). 2010 Oct; 3(10):1259-64. Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD. PMID: 20823291.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    61. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010 Jun 07; 207(6):1209-21. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. PMID: 20498019.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    62. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 2010 Jun 01; 70(11):4346-56. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. PMID: 20460528.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    63. Genetic relicts from the origin of ALL. Blood. 2010 Apr 29; 115(17):3424-5. Müschen M. PMID: 20430963.
      View in: PubMed   Mentions: 1     Fields:    
    64. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. J Cell Biochem. 2010 Mar 01; 109(4):818-27. Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG. PMID: 20069569.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    65. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010 Apr; 24(4):813-20. Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N. PMID: 20111071.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    66. Pre-B cell receptor signaling in acute lymphoblastic leukemia. . 2009 Dec; 8(23):3874-7. Nahar R, Müschen M. PMID: 19901533.
      View in: PubMed   Mentions:
    67. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010 Feb 04; 115(5):1049-53. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. PMID: 19965645.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    68. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009 Sep 08; 16(3):232-45. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. PMID: 19732723.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    69. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009 Aug 03; 206(8):1739-53. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M. PMID: 19620627.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    70. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008 Dec 12; 135(6):1130-42. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. PMID: 19070581.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    71. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 2008 Dec; 93(12):1814-21. Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Müschen M, Foà R, Baccarani M, Martinelli G. PMID: 18838475.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    72. Highlight: self-renewal signaling in stem cells. Biol Chem. 2008 Jul; 389(7):787. Müschen M. PMID: 18681824.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    73. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biol Chem. 2008 Jul; 389(7):897-903. Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M. PMID: 18681827.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    74. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007 Oct 25; 6:67. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N. PMID: 17958915.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    75. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007 May 14; 204(5):1157-66. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. PMID: 17485517.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    76. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 2007 Mar; 26(3):323-33. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. PMID: 17331747.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    77. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol. 2006 Jun; 209(2):250-7. Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R. PMID: 16508921.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    78. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene. 2006 Aug 24; 25(37):5180-6. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. PMID: 16636677.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    79. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene. 2006 Aug 17; 25(36):5056-62. Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. PMID: 16568084.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    80. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene. 2006 Feb 16; 25(7):1118-24. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M. PMID: 16205638.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    81. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13266-71. Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M. PMID: 16141323.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    82. B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet. 2005 Sep; 161(2):187-8. Soh BN, Klein F, Feldhahn N, Müschen M. PMID: 16102593.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    83. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med. 2005 Jun 06; 201(11):1837-52. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. PMID: 15939795.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    84. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2005 Jan 01; 174(1):367-75. Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M. PMID: 15611260.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    85. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. Eur J Immunol. 2004 Dec; 34(12):3614-22. Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H. PMID: 15549729.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    86. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. . 2004 Jul; 3(7):858-60. Klein F, Feldhahn N, Müschen M. PMID: 15254401.
      View in: PubMed   Mentions:
    87. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004 Jul 19; 200(2):123-35. Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P. PMID: 15263023.
      View in: PubMed   Mentions: 223     Fields:    Translation:HumansAnimalsCells
    88. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004 Mar 01; 199(5):673-85. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. PMID: 14993251.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    89. Epstein-Barr virus and the B cell: a secret romance. Trends Microbiol. 2003 Jun; 11(6):243-5. Schuster VH, Müschen M. PMID: 12823936.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    90. T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6747-52. Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M. PMID: 12738882.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    91. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003 Mar; 17(3):503-5. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H. PMID: 12514119.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    92. Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A. 2002 Jul 23; 99(15):10014-9. Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM. PMID: 12119411.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    93. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002 Feb; 23(2):75-80. Müschen M, Rajewsky K, Krönke M, Küppers R. PMID: 11929130.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    94. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer. 2001 Apr 15; 92(2):309-10. Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. PMID: 11291062.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    95. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001 Mar 01; 61(5):2080-4. Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. PMID: 11280769.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    96. Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. Lab Invest. 2001 Mar; 81(3):289-95. Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML. PMID: 11310822.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    97. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood. 2001 Feb 01; 97(3):818-21. Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. PMID: 11157505.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    98. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med. 2000 Dec 18; 192(12):1833-40. Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. PMID: 11120779.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    99. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 2000 Oct 15; 60(20):5640-3. Müschen M, Re D, Bräuninger A, Wolf J, Hansmann ML, Diehl V, Küppers R, Rajewsky K. PMID: 11059754.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    100. CD95 ligand expression as a criterion of malignant transformation in breast cancer. J Pathol. 2000 Aug; 191(4):468-70. Müschen M, Beckmann MW. PMID: 10918226.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    101. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000 Jan 17; 191(2):387-94. Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. PMID: 10637283.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    102. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000; 78(6):312-25. Müschen M, Warskulat U, Beckmann MW. PMID: 11001528.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    103. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology. 2000 Jan; 99(1):69-77. Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. PMID: 10651943.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    104. CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 1999 Nov; 189(3):378-86. Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. PMID: 10547600.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    105. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol. 1999 Sep; 155(3):915-25. Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. PMID: 10487849.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    106. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology. 1999 Mar; 116(3):666-77. Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D. PMID: 10029626.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    107. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer. 1999 Feb 09; 80(4):564-72. Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. PMID: 9935158.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    108. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest. 1998 Dec 01; 102(11):1920-6. Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC. PMID: 9835616.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    109. Deranged CD95 system in a case of Churg-Strauss vasculitis. Gastroenterology. 1998 Jun; 114(6):1351-2. Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. PMID: 9618660.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    110. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology. 1998 Jan; 27(1):200-8. Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. PMID: 9425938.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells